Equities

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Actions
  • Price (USD)31.52
  • Today's Change2.13 / 7.25%
  • Shares traded460.56k
  • 1 Year change-9.50%
  • Beta1.0115
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

  • Revenue in USD (TTM)9.93m
  • Net income in USD-366.91m
  • Incorporated2007
  • Employees390.00
  • Location
    Agios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
  • Phone+1 (617) 649-8600
  • Fax+1 (302) 655-5049
  • Websitehttps://www.agios.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Syndax Pharmaceuticals Inc126.58m-13.95m1.51bn59.00--4.45--11.91-0.2194-0.21942.125.620.4225--49.342,145,356.00-4.65-27.65-5.07-30.65-----11.02-163.32---123.660.00005--9,109.56158.09132.34---13.15--
Rhythm Pharmaceuticals Inc16.67m-181.49m1.52bn140.00--5.35--91.29-3.59-3.590.32935.040.0447----119,035.70-48.69-41.92-52.69-45.5991.95---1,089.06-14,334.50---176.070.206------48.05---16.31--
Alvotech SA77.59m-12.03m1.53bn805.00----114.9619.71-2.89-2.890.5544-1.19------96,382.61--------28.93---15.50--0.6624--1.77---42.86--40.31------
Day One Biopharmaceuticals Inc0.00-124.01m1.56bn102.00--4.30-----1.96-1.960.004.940.00----0.00-36.17---37.50--------------0.00-------321.26------
Kymera Therapeutics Inc45.96m-153.84m1.58bn169.00--3.07--34.28-2.94-2.940.8789.370.0718--20.63---24.02---28.09-------334.72------0.0035--114.00---83.40------
Twist Bioscience Corp203.56m-217.86m1.58bn652.00--1.99--7.74-4.03-4.033.7714.010.24483.366.12---26.19-35.74-28.86-39.8341.3832.59-107.02-136.186.15--0.00--53.8380.02-43.24------
Dynavax Technologies Corp733.26m320.63m1.60bn311.006.253.204.862.182.012.014.593.920.76423.044.442,357,753.0033.89-24.7656.75-34.8964.72--44.35-76.493.40--0.3066--844.00108.91195.89--4.09--
Petro Usa Inc0.00-8.87k1.60bn-----------0.1547-0.15470.00-0.0005---------------------------30.68--------53.07------
Prime Medicine Inc0.00-170.69m1.60bn150.00---------1.81-1.810.001.800.00----0.00-54.84---58.33-------------17.490.00---100.00---3,542.31------
Agios Pharmaceuticals Inc9.93m-366.91m1.61bn390.00--1.54--162.62-6.72-6.650.181819.130.0073--1.5825,461.54-26.96-38.82-28.11-43.4287.00---3,694.98-1,199.3814.55--0.0011-------8.26---10.35--
Myriad Genetics, Inc.661.40m-74.60m1.65bn2.40k--1.80--2.49-0.9274-0.96118.2311.330.519210.156.76275,583.30-5.86---6.73--70.68---11.28--2.58-53.450.00--------------
Ventyx Biosciences Inc0.00-90.98m1.67bn31.00--4.36-----1.79-1.790.006.770.00----0.00-31.97---34.88--------------0.00-------202.75------
Prometheus Biosciences Inc7.19m-132.91m1.68bn72.00--7.20--233.24-3.35-3.350.18165.560.0245--8.8899,902.78-45.24---48.45-------1,847.71------0.00--154.60---189.65------
Dice Therapeutics Inc0.00-76.86m1.71bn65.00--5.25-----2.05-2.050.006.840.00----0.00-24.50---25.49--------------0.00--30.36---106.24------
EQRx Inc0.00-145.69m1.71bn242.00--1.19-----0.3087-0.30870.002.940.00----0.00-14.37---15.03--------------0.00------59.99------
Celldex Therapeutics, Inc.1.08m-105.99m1.73bn132.00--5.00--1,601.74-2.27-2.270.0237.330.0026--5.598,166.67-25.56-35.72-26.53-38.58-----9,831.73-1,172.07----0.00---37.30-7.28-17.95---14.61--
Data as of Dec 02 2022. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

56.63%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 30 Sep 20225.15m9.39%
The Vanguard Group, Inc.as of 30 Sep 20225.13m9.37%
Bellevue Asset Management AGas of 30 Sep 20224.06m7.40%
BlackRock Fund Advisorsas of 30 Sep 20223.84m7.00%
Rock Springs Capital Management LPas of 30 Sep 20223.06m5.58%
SSgA Funds Management, Inc.as of 30 Sep 20222.63m4.81%
First Trust Advisors LPas of 30 Sep 20221.99m3.62%
Armistice Capital LLCas of 30 Sep 20221.92m3.51%
Fidelity Management & Research Co. LLCas of 30 Sep 20221.75m3.20%
Goldman Sachs Asset Management LPas of 30 Sep 20221.51m2.75%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.